spartalizumab (PDR001) / Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
spartalizumab (PDR001) / Novartis
COMBI-i, NCT02967692 / 2016-002794-35: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Checkmark From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Checkmark From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Checkmark From COMBI-i trial in combination with spartalizumab and Mekinist for BRAFV600 metastatic melanoma
More
Completed
3
569
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
08/20
08/24
Precision Promise, NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27

Download Options